Intelligent assistive technology applications to dementia care: Current capabilities, limitations, and future challenges

American Journal of Geriatric Psychiatry

Volumn 17, Issue 2, 2009, Pages 88-104

  Bharucha, Ashok J ^a,c   Anand, Vivek ^b   Forlizzi, Jodi ^b   Dew, Mary Amanda ^a   Reynolds, Charles F ^a   Stevens, Scott ^b   Wactlar, Howard ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Artificial intelligence; Assistive technology; Biosensors

Indexed keywords

AGING; ARTIFICIAL INTELLIGENCE; ASSISTIVE TECHNOLOGY; BIOSENSOR; BRAIN HYPOXIA; CAREGIVER BURDEN; CLINICAL STUDY; COGNITIVE DEFECT; COMPUTER; DATA BASE; DEMENTIA; DEVICE; ENGINEERING; FUTUROLOGY; HEALTH CARE; HEALTH CARE NEED; HUMAN; PHYSICAL DISABILITY; REVIEW; TECHNICAL AID; TRAUMATIC BRAIN INJURY; WESTERN HEMISPHERE; AGED; AGNOSIA; ALZHEIMER DISEASE; APHASIA; ARTICLE; CAREGIVER; DISABLED PERSON; GENERAL MEDICAL AIDS; GENETIC PROCEDURES; MEDICAL TECHNOLOGY; MEMORY DISORDER; PALLIATIVE THERAPY; SELF HELP;

AGED; AGNOSIA; ALZHEIMER DISEASE; APHASIA; BIOSENSING TECHNIQUES; CAREGIVERS; COGNITION DISORDERS; DATABASES AS TOPIC; DEMENTIA; DISABLED PERSONS; HUMANS; MEMORY DISORDERS; PALLIATIVE CARE; SELF-HELP DEVICES; SENSORY AIDS; TECHNOLOGY, MEDICAL;

EID: 60849108338     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e318187dde5     Document Type: Article

References (10)

1. Forest Pharmaceuticals, Inc.: Namenda prescribing information, St. Louis, 2007
2. Bakchine S, Loft H: Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomized, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2007; 11:471- 479
3. Peskind ER, Potkin SG, Pomara N, et al: Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14:704-715
4. Reisberg B, Doody R, Stoffler A, et al: Memantine in moderate-tosevere Alzheimer's disease. N Engl J Med 2003; 348:1333-1341
5. Tariot PN, Farlow MR, Grossberg GT, et al: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324
6. van Dyck CH, Tariot PN, Meyers B, et al: A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21:136-143
7. Winblad B, Poritis N: Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14:135-146
8. Forest Pharmaceuticals, Inc.: Forest laboratories clinical trial registry, 2005. Available at: http://www.forestclinicaltrials.com/CTR/ CTRController/CTRCompleted. Accessed April 28, 2008
9. Kornhuber J, Kennepohl EM, Bleich S, et al: Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 2007; 46:599-612
10. Periclou A, Ventura D, Rao N, et al: Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006; 79:134-143